We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Pioglitazone: inexpensive; very effective at reducing HbA<sub>1c</sub>; no evidence of bladder cancer risk; plenty of evidence of cardiovascular benefit.
- Authors
Ryder, Robert E. J.; DeFronzo, Ralph A.
- Abstract
The authors comment on the study by Ripamonti et al that linked the anti-diabetes drug pioglitazone to bladder cancer. They claim that many subsequent studies on the possible link of pioglitazone to bladder cancer showed no connection. They believe that studies focused on this link is no longer appropriate and instead, pioglitazone studies should focus more on whether combining pioglitazone with sodium-glucose co-transporter agonists leads to increased reduction of cardiovascular events.
- Subjects
BLADDER tumors; COST control; GLYCOSYLATED hemoglobin; PIOGLITAZONE; DISEASE risk factors
- Publication
Diabetic Medicine, 2019, Vol 36, Issue 9, p1185
- ISSN
0742-3071
- Publication type
Article
- DOI
10.1111/dme.14053